CG Oncology (CG Oncology) Current Deferred Taxes Liabilities : $0.00 Mil (As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is CG Oncology Current Deferred Taxes Liabilities?

Current Deferred Taxes Liabilities represent future tax liabilities, resulting from temporary differences between book (accounting) value of assets and liabilities and their tax value, or timing differences between the recognition of gains and losses in financial statements and their recognition in a tax computation. Deferred tax liabilities generally arise where tax relief is provided in advance of an accounting expense, or income is accrued but not taxed until received.

CG Oncology's current deferred tax liabilities for the quarter that ended in Mar. 2024 was $0.00 Mil.

CG Oncology Current Deferred Taxes Liabilities Historical Data

The historical data trend for CG Oncology's Current Deferred Taxes Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CG Oncology Current Deferred Taxes Liabilities Chart

CG Oncology Annual Data

Trend

Dec21

Dec22

Dec23

Current Deferred Taxes Liabilities

CG Oncology Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
Current Deferred Taxes Liabilities	Get a 7-Day Free Trial			-	-	-	-	-

CG Oncology Current Deferred Taxes Liabilities Related Terms

Thank you for viewing the detailed overview of CG Oncology's Current Deferred Taxes Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

CG Oncology (CG Oncology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CG Oncology Inc (NAS:CGON) » Definitions » Current Deferred Taxes Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.

CG Oncology (CG Oncology) Headlines

From GuruFocus

CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024

By Marketwired • 04-24-2024